Glancy Prongay & Murray Commences Investigation on Behalf of CytRx Corporation Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

CytRx is a biopharmaceutical research and development company that specializes in oncology.

On July 11, 2016, CytRx released the results of its Phase 3 clinical trial of aldoxorubicin, a product candidate designed for patients with soft tissues sarcomas (“STS”), which did not show noticeable improvement over other widely used cancer drugs. Additionally, the Company announced that nearly half of the patients in the Phase 3 trial were excluded from the data due to a partial clinical hold back in November 2014, and that the Company intended to conduct a second analysis. Following this disclosure, shares of CytRx fell nearly 60% on July 12, 2016, thereby injuring investors.

If you purchased CytRx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by e-mail please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160720005379/en/